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 Abbreviations: 
EAE: experimental allergic encephalomyelitis;  
3HAA: 3-hydroxyanthranilic acid;  
3HK: 3-hydroxykynurenine;  
HD: Huntington’s disease;  
sHLA-G: soluble Human Leucocyte Antigen-G; 
IDO: indoleamine-2,3-dioxygenase;  
IFN-: interferon-γ 
IL-: interleukin-;  
KMO: kynurenine-3-monoxygenase 
NMDA: N-methyl-D-aspartate;  
TLR: Toll-Like Receptor 
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Running title:   
Kynurenines and Huntington’s disease 
 
Abstract 
There is substantial evidence that abnormal concentrations of oxidised tryptophan 
metabolites, produced via the kynurenine pathway, contribute to progressive 
neurodegeneration in Huntington's disease. We have now examined the blood levels 
of these metabolites in patients at different stages of Huntington's disease, assessed 
both in terms of clinical disease severity and numbers of CAG repeats. Close 
relatives of the patients were included in the study as well as unrelated healthy 
controls. Levels of lipid peroxidation products, the pro-inflammatory cytokine 
interleukin-23 (IL-23) and the soluble human leucocyte antigen-G (sHLA-G) were 
also measured. There were lower levels of tryptophan and a higher kynurenine : 
tryptophan ratio, indicating activation of indoleamine-2,3-dioxygenase (IDO), in the 
most severely affected group of patients, with increased levels of IL-23 and sHLA-G. 
Marked correlations were noted between IL-23 and the patient severity group, 
anthranilic acid levels and the number of CAG repeats, and between anthranilic acid 
and IL-23, supporting our previous evidence of a relationship between anthranilic 
acid and inflammatory status. Tryptophan was negatively correlated with symptom 
severity and number  of CAG repeats, and positively correlated with sHLA-G. The 
results support the proposal that tryptophan metabolism along the kynurenine 
pathway in Huntington's disease is related to the degree of genetic abnormality, to 
clinical disease severity and to aspects of immunopathogenesis.  
 
Key-words:  Huntington’s disease; kynurenine; kynurenic acid; anthranilic acid; 
tryptophan IL-23, sHLA-G. 
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Introduction 
Huntington's disease (HD) is an autosomal dominant disorder in which there is 
extensive degeneration of neurons in the striatum and neocortex.  The clinical 
progression is variable but includes a movement disorder, cognitive decline and often 
a psychiatric component. Although a clear link has been made between the presence 
of the abnormal huntingtin protein, with an expanded series of glutamine residues 
close to its N-terminus (coded by CAG nucleotide triplet repeats) and the 
development of HD, the mechanisms by which this abnormality leads to neuronal 
loss remains unclear (Kuemmerle et al., 1999; Bates, 2003; Roze et al., 2008).  
One possibility that has received much attention is that the kynurenine 
pathway (Figure 1), for the oxidative metabolism of tryptophan, contributes 
significantly to the neurodegeneration. This interest was originally focused on 
quinolinic acid, an endogenous tryptophan metabolite which is a selective agonist at 
N-methyl-D-aspartate (NMDA) receptors (Stone & Perkins, 1981; Stone, 2001; Stone 
& Darlington, 2002), with the resulting ability to induce excitotoxicity (Schwarcz et al., 
1983). The administration of quinolinic acid into the striatum produces a pattern of 
cellular, neurochemical and behavioural changes closely resembling those seen in 
human HD (Beal et al., 1991a,b; Vecsei et al., 1991; Storey et al., 1994; Huang et 
all.,1995; Stone, 2001; Schwarcz et al., 2009). A role for glutamate, especially acting 
at NMDA receptors, continues to be strongly supported by evidence from patients 
and animal models (Cowan et al., 2008; Miller et al., 2008; Hassel et al., 2008; Heng 
et al., 2009). 
However, other tryptophan metabolites in the kynurenine pathway are also 
likely to be relevant. Kynurenic acid is an antagonist at glutamate receptors (Perkins 
& Stone, 1982) and nicotinic cholinoceptors (Hilmas et al., 2001; Stone, 2007), while 
3-hydroxykynurenine (3HK) and 3-hydroxyanthranilic acid (3HAA) are redox active 
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compounds able to generate oxidative stress via the production of hydrogen peroxide 
under physiological conditions (Eastman & Guilarte, 1989, 1990; Nakagami et al., 
1996; Okuda et al., 1996, 1998; Guidetti et al., 2000; Giles et al., 2003). Previous 
studies of the levels of these various tryptophan metabolites in HD has shown 
changes in several of them, supporting the view that the pathway may contribute to 
HD symptomatology. Kynurenic acid concentrations are lower in human post-mortem 
HD brain (Beal et al., 1992; Jauch et al., 1995), and an increased ratio of kynurenine 
to kynurenic acid has also been reported (Beal et al., 1990). There is increased 
enzymic activity of 3-hydroxyanthranilic acid oxygenase, which converts 3-
hydroxyanthranilic acid into quinolinic acid in HD striatum (Schwarcz et al., 1988), 
with increased amounts of (3HK) - the precursor of 3HAA - in the putamen, frontal 
and temporal cortex of post mortem HD brains (Reynolds and Pearson, 1989; 
Pearson & Reynolds, 1992; Guidetti et al., 2000). 
A previous analysis from this laboratory (Stoy et al., 2005c) showed that the 
kynurenine:tryptophan ratio was increased in the blood of HD patients compared with 
control subjects, indicating increased activity of the first enzymes of tryptophan 
oxidation: tryptophan-2,3-dioxygenase, found primarily in the liver or indoleamine-
2,3- dioxygenase found in neurones, glia and immune system cells (IDO). These 
changes were accompanied by raised levels of inflammatory markers such as C-
reactive protein, neopterin and lipid peroxidation products compared with controls. 
Changes were also demonstrated in the ratio of kynurenic acid:kynurenine, while 
levels of the redox-active 3HAA was decreased in HD patients, possibly as an 
adaptation to inflammation and increased oxidative stress. Overall, the results 
supported the view that tryptophan oxidation via the kynurenine pathway was altered 
in patients with HD. 
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That previous study, however, involved only hospitalised patients with 
advanced HD and we have now attempted to determine further the relevance of 
tryptophan metabolism by the kynurenine pathway by examining a series of patients 
at different stages of HD defined by the clinical assessment of symptom severity and 
by the length of the huntingtin gene CAG nucleotide triplet repeats.  
Finally, there is growing interest in interleukin-23 (IL-23) and the soluble 
human leucocyte antigen-G (sHLA-G) in the expression of inflammatory conditions of 
the CNS, with the latter having a possible relationship to tryptophan metabolism 
(Gonzalez-Hernandez et al., 2005). We have, therefore, included measurements of 
these proteins in the full cohort of patients, relatives and controls. 
 
 
Methods 
Patients 
It is well established that the length for CAG triplet expansion which is 
considered to be normal is up to around 36;  in general subjects with 36 or fewer 
repeats have no evidence of brain pathology, motor or psychiatric abnormalities 
attributable to HD, while people with 40 or more repeats almost invariably have 
symptomatic evidence of the disorder. Patients with 37-39 repeats (reduced 
penetrance alleles) show reduced levels of symptoms. We have, therefore, defined 
patients as gene negative who had 36 or fewer CAG repeats and as gene positive if 
they had 37 or more repeats.  The motor section of the Unified Huntington's Disease 
Rating Scale (The Huntington Study Group, 1986) was chosen as the most objective 
single measure of clinical disease severity currently available with the advantage that 
a score could be reliably established by a quick neurological examination. On this 
basis, participants were assigned to three clinical groups. The range of subjects 
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included those with no gene expansion and no overt clinical symptoms (group 0-, this 
group included subjects who were normal healthy volunteers working in Epsom 
General Hospital or associated laboratories and relatives of HD patients showing no 
gene expansion or symptoms), those with CAG expansion but no symptoms (0+), as 
well as patients with CAG expansions and mild-to-moderate disease severity (1+) or 
severe disease severity (2+). Inclusion of the 0- group allowed us to assess whether 
kynurenine pathway changes might occur in the relatives of patients with overt HD, 
even though those relatives had no discernible, accepted signs of the disease. The 
0+ group should indicate whether the kynurenine pathway was affected in gene 
positive subjects independently of the existence of overt disease at the time of 
interview i.e. perhaps at an early stage of pathogenesis. The numbers of patients 
recruited to the different groups were as follows:- group 0-, n=29 (20f, 9m); group 0+, 
n=19 (14f, 5m); group 1+, n=14 (9f,5m); group 2+, n=40 (24f,16m), healthy controls 
n=11 (9f, 2m). None of the control subjects or patients reported any infections or 
illness within the previous 2 weeks before blood sampling and none showed any 
signs of infection at the time of sampling. Similarly none of the control subjects or 
patients had any psychiatric or neurological illness (other than HD) at the time of 
sampling.  
Ethical approval for the study was obtained from the Ethical Committee of the 
Epsom and St Helier University Hospitals NHS Trust and all Research Governance 
requirements were achieved.  
 
Blood sampling 
Blood was collected by an experience phlebotomist from HD family members 
and controls in or near to their homes. Venous blood samples (25ml) were taken 
either into EDTA before being frozen in dry ice and transported to storage at -20°C 
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(for CAG repeats) or were allowed to clot at room temperature before being 
centrifuged and the serum removed for storage at -80°C until extraction and analysis. 
 
CAG repeats 
DNA was extracted from 4ml frozen blood in EDTA using the GeneCatcherTM 
automated blood kit by Invitrogen on the Tecan EVO150 liquid manual handling 
system in batches of 8 patients.   
Sixty μl GeneCatcherTM magnetic beads and 12ml of 1 X GeneCatcherTM Lysis 
buffer (L12) were aspirated into eight 50ml falcon tubes and 4 sequential 1ml aliquots 
of patient blood added and mixed. The tubes were agitated at 300 rpm for 1 minute 
and incubated for 4 minutes at room temperature before discarding the supernatant. 
Ten ml of 1 X GeneCatcherTM Lysis buffer (L12) was added to each pellet before 
further agitation and removal of supernatant, and this process was repeated.  Three 
ml of protease buffer and 40μl of protease were added to each tube and shaken to 
help resuspend the bead pellet after which the tubes were heated to 65-70°C for 5 
minutes.  The samples were mixed by trituration to disperse the bead/DNA pellet, 
incubated for another 10 minutes, and then 3ml of 100% isopropanol was added to 
each tube.  After shaking at 400 rpm for 2 minutes until visible aggregates had 
formed, the tubes were heated once more and the supernatant discarded. Addition of 
3ml of 50% (v/v) isopropanol was followed by further agitation, addition of 250μl of 
GeneCatcherTM Wash buffer (W12), supernatant removal and addition of 400μl of 
Elution buffer (E5) to each tube.  After further rounds of shaking, incubation at 65-
70°C and mixing by  trituration, the supernatant containing the DNA was removed 
from the bead pellet and transferred to a sterile microcentrifuge tube, ready for 
further analysis.   
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PCR analysis 
Testing for CAG repeat sequences was carried out by fluorescent PCR 
analysis using the HD1 and HD3 primers that flank the CAG repeat region in exon 1 
of the HD gene (described by the HD collaborative research group 1993).  The PCR 
was set up containing 0.025U Qiagen Taq with associated 1 X buffer (with 
magnesium) & Q solution, 0.25mM dNTPs (C, T, A, deaza-GTP), 0.5μM HD1 (dye-4 
labelled) and HD3, 2μl patient DNA (1/10 dilution) in a total reaction volume of 20μl.  
The PCR  was then amplified on a Hybaid PCR machine using the following 
parameters: 94°C for 4 minutes, then 30 cycles of 94°C for 45 seconds, 67.5°C for 45 
seconds, 72°C for 45 seconds and a final step of 72°C for 10 minutes.  For some 
samples where the HD1/3 PCR result was not conclusive/informative, a second PCR 
was performed using two alternative primers HD2 and HD4+ which are further out 
from the CAG repeat and incorporate an additional polymorphic CCG repeat as well 
as the CAG repeat in the PCR fragment. The CCG repeat is polymorphic and 
therefore, even when the CAG repeat is the same size for each allele, the PCR is 
likely to produce two different sized products.  This PCR involved the substitution of 
HD2 (dye-3 labelled) and HD4+ in to the above PCR reaction conditions. The 
annealing temperature for the PCR reaction was also 63°C instead of 67.5°C.  PCR 
primer sequences are as follows (5’ to 3’):  
HD1- : ATGAAGGCCTTCGAGTCCCTCAAGTCCTTC  
HD3- : GGCGGTGGCGGCTGTTGCTGCTGCTGCTGC  
HD2- : AAACTCACGGTCGGTGCAGCGGCTCCTCAG  
HD4+: GCCATGGCGACCCTGGAAAAGC. 
1μl PCR product were mixed with 40μl sample loading solution and 0.5μl 
600PA size standard and run on a Beckman Coulter CEQ 8000 sequencer using 
Frag4 run module and auto-analysed using HD analysis parameters.  Two positive 
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expansion controls and a negative control were also included in each run for quality 
control.  In order for a result to be valid, all lanes need to have injected correctly, the 
size standard needs to have migrated the same in each lane, all peaks need to have 
a fluorescence of above 10,000 rfus, the positive controls need to give the expected 
results and the PCR negative control needs to have no peaks above 5% of those 
seen in the patient samples.  The auto-analysis software automatically labels the one 
or two alleles present and determines the number of repeat units that the peak 
corresponds to (although this is also checked manually).  This is done by calculating 
the size of the allele in base pairs, subtracting the constant region amplified by the 
primers (47bp) and then dividing the remaining bps by 3 to give the number of CAG 
repeats.  This number is then increased by 2 to allow for a Beckman migration 
correction factor.  The error margin of the assay method is ±1 repeat.  Exact allele 
sizes are not calculated for products of the HD2/HD4+ PCR, as two polymorphic 
regions are present in the PCR product.     
 
Analysis of Kynurenines by HPLC 
L-tryptophan and L-kynurenine were quantified using absorbance detection 
spectrometry, whereas kynurenic acid, 3-hydroxyanthranilic acid and anthranilic acid 
were quantified using fluorescence detection. The method used for tryptophan, 
kynurenine and kynurenic acid was based on that presented by Hervé et al. (1996) 
and the method for 3-hydroxyanthranilic acid and anthranilic acid was modified from 
that described by Cannazza et al. (2003).  
During sample preparation, serum samples were kept on ice. To 500μl serum, 
100μl of internal standard (240μM 3-nitro-L-tyrosine) and 50μl 2mM ascorbic acid 
were added, followed by 150μl 2M perchloric acid and 200μl water.  Samples were 
shaken and then centrifuged at 5000g for 10 minutes at 4°C. The supernatants were 
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collected and filtered using centrifugation at 10,000g for 10 minutes at 4°C, prior to 
injection of 100μl onto the HPLC column.   
Isocratic reversed-phase HPLC was performed at 37°C, using a Waters HPLC 
system. For tryptophan, kynurenine and kynurenic acid determination, separation 
was achieved using a Synergi Hydro column (250 x 4.6mm I.D., particle size 4μm;  
Phenomenex, Macclesfield, Cheshire, UK), with detection by a Waters 2487 dual 
wavelength absorbance detector and a Waters 474 fluorescence detector, connected 
in series. Tryptophan was determined by absorption spectrometry at 250nm and 
kynurenine at 365nm.  The internal standard, 3-nitrotyrosine, was quantified at 
365nm.  Kynurenic acid was determined by fluorescence detection (excitation 
344nm, emission 390nm). The mobile phase was 50mM acetic acid, 100mM zinc 
acetate containing 1.5% acetonitrile using a flow rate of 1ml/min.  Zinc acetate 
enhances the fluorescence of kynurenic acid (Shibata, 1988).   
3-hydroxyanthranilic acid and anthranilic acid were separated using a Synergi 
Hydro column (250 x 4.6mm I.D., particle size 4μm, Phenomenex) and fluorescence 
detection (excitation 320nm, emission 420nm).  The mobile phase was 25mM 
sodium acetate buffer at pH5.5, at a flow rate of 1ml/min. 
The limits of detection using an injection volume of 100μl and a signal-to-noise 
threshold of 3, were: tryptophan 20pmoles, kynurenine 1pmole, kynurenic acid 
0.2pmoles, 3-hydroxyanthranilic acid 10fmoles, and anthranilic acid 20fmoles on 
column. Recoveries determined using blood samples spiked with standards of the 
measured compounds were between 90 and 110% for tryptophan, kynurenine, 
kynurenic acid, 3-hydroxyanthranilic acid and anthranilic acid.  
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IL-23 
Levels of IL-23 were determined in serum using a commercially available Biosource 
human IL-23 immunoassay kit (Invitrogen, Paisley, UK). This kit detected the human 
IL-23 heterodimeric protein consisting of subunits p19 and p40, and did not recognise 
the monomeric forms of the p19 and p40 subunits.   
 
sHLA-G 
The concentration of soluble HLA-G was measured in serum samples using an 
ExBIO/BioVendor ELISA assay kit supplied by AXXORA (Nottingham, UK). The 
assay was specific for the HLA-G1 and HLA-G5 isoforms.    
 
Lipid peroxidation 
The lipid peroxidation products malondialdehyde and 4-hydroxynonenal were 
measured in serum using a Bioxytech LPO-586 colorimetric assay (Biostat, 
Stockport, UK). The analysis involved the reaction of N-methyl-2-phenylindole with 
these peroxidation products to form a stable chromogenic indolic dimer which was 
detected spectrophotometrically at 595nm using a microplate reader.   
 
Statistics  
All data are presented as the mean ± 1 standard error of the mean. Ordinary analysis 
of variance (ANOVA) followed by Dunnett’s post-test was carried out to compare 
healthy controls with each of the HD patient groups. Where the data was non-
parametric ANOVA was followed by Dunn’s post-test. Correlations between variables 
were obtained using a correlation matrix which generated the Spearman correlation 
coefficients and level of statistical significance. In all cases a significance threshold of 
5% (p<0.05) was employed.   
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Results 
Kynurenines  
The level of tryptophan in the serum shows a trend to decrease as the severity 
of HD increased (Fig. 2A). This became significant in the 2+ group of patients who 
are both gene positive and exhibit the most severe symptoms. Even though there 
was no similar, significant change in the absolute levels of kynurenine (Fig. 2B), the 
ratio between the substrate and product of IDO activity (the k:t ratio) was altered 
significantly in the 2+ patients (Fig. 2C).  
There were no significant changes in the levels of kynurenines beyond 
kynurenine itself, including kynurenic acid, which represents the product of activity in 
the kynurenine aminotransferase enzymes (Fig. 3A), 3-hydroxyanthranilic acid 
(3HAA) which is the product of kynurenine mono-oxygenase and kynureninase 
activity (Fig. 3B), or anthranilic acid which is produced solely by kynureninase activity 
(Fig. 3C). 
 
Kynurenine correlations 
 The use of absolute values across patient groups is dependent on the means 
and variances of the populations assessed and can mask specific relationships 
between individual parameters across the population. Correlations generate more 
useful information about the relationships between factors in individual patients. In 
this case, there were clear and highly significant negative correlations between the 
levels of tryptophan and the patient group (0-, 0+, 1+ or 2+) (Table 1), and between 
tryptophan levels and CAG repeat length (Table 1). These were all negative 
correlations suggesting a relationship with the activation of tryptophan metabolism by 
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IDO, this possibility being supported by the strong positive correlations between k:t 
ratio and group, age and CAG repeats. In contrast, there were no significant 
correlations between kynurenine levels and patient group or CAG repeats (Table 1).  
The relationship with age could represent a cause or a consequence of the 
presence of disease. Indeed, several groups have noted similar correlations between 
tryptophan, k:t ratios or kynurenic acid levels and age (Kepplinger et al., 2005; 
Pertovaara et al., 2006). Indeed, one of the difficulties in studies of 
neurodegenerative disorders is their tendency to be age-related. However, it is very 
unlikely that the changes observed in the present study are attributable primarily to 
age, for three reasons. Firstly, tryptophan levels were not correlated with age in our 
patient population (Table 1). Secondly, there was little difference in the age 
distribution of patients across the classification groups (Fig. 4). An analysis of 
variance revealed a significant difference across the groups (F(4,112)=8.96, p < 
0.0001), but only the mean age of the 0+ group of patients was significantly different 
from the control group (p < 0.05, Dunnett’s test). Thirdly, even if the relationship 
between kynurenines and disease severity was caused by the progressive worsening 
of symptoms with age, the measurement of CAG repeat length was performed in 
parallel on the same blood samples used for the other analyses and age cannot, 
therefore, account for the genetic correlations observed. There was no correlation 
between CAG repeats and age (r = 0.10, p = 0.27). 
Finally there were several correlations between tryptophan metabolites and 
inflammatory markers (see below and Table 1). 
 
Inflammatory markers  
Although the absolute levels of lipid peroxidation products, which are 
commonly used to reflect the degree of oxidative stress in patients, were not 
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changed in these patients (Fig. 5A), there were significant differences in both IL-23 
(Fig. 5B) and sHLA-G (Fig. 5C). For both of these compounds, there was a clear 
trend to an increase in absolute values with increasing severity of the disease, with 
significant differences appearing in the most severely affected subjects. 
 
Inflammatory marker correlations 
IL-23 levels correlated with the overall patient classification group of disease 
severity (r = 0.414, p = 0.0006), age (r = 0.288, p = 0.0022) and the number of CAG 
repeats (r = 0.283, p = 0.0026). The levels also correlated with the k:t ratio, levels of 
kynurenic acid and levels of anthranilic acid (Table 1). Levels of tryptophan were 
correlated with sHLA-G. 
 
 
Discussion 
 Since the first reports by Beal et al., (1986, 1991a,b) that intrastriatal 
administration of quinolinic acid to rodents produced a pattern of neurotransmitter 
and neuropeptide changes closely similar to that seen in human post-mortem HD 
tissue, there has been a growing interest in the role of this compound and other 
tryptophan metabolites in the disease (Stone, 1993, 2001). Indeed, quinolinic acid 
lesions of the striatum have become widely accepted as an experimental model for 
HD (Schwarz et al., 1992; Popoli et al., 1994; Hughes et al., 1999). The fidelity of the 
quinolinic acid model is increased by localised administration into the posterior 
putamen of non-human primates (Burns et al., 1995).  
There is now strong evidence that an over-expression of the abnormal 
huntingtin gene contributes to the induction of HD symptoms in humans and to the 
striatal characteristics of HD in mouse models (Carter et al., 1999; Sathasivam et al., 
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1999; Usdin et al., 1999), so it is intriguing that administration of quinolinic acid into 
the striatum can induce an increased expression of huntingtin (Tatter et al., 1995), 
raising questions about which is causal and which is effect. Perhaps a primary 
toxicity caused by kynurenine metabolites could induce huntingtin as the 
cytoprotective response postulated by some authors (Kuemmerle et al. 1999; Bates, 
2003). 
Interest in the kynurenine pathway has been strengthened by evidence that 
levels of kynurenic acid and the redox-active metabolite 3HK are also altered in HD 
brain compared with controls (Reynolds and Pearson, 1989; Pearson and Reynolds, 
1992; Guidetti et al., 2000). The former change adds to the possibility that the degree 
of activation of NMDA receptors (by glutamate or quinolinic acid) and their blockade 
by kynurenic acid could contribute to the development of HD, while the changes of 
3HK would be consistent with increased oxidative stress in the disorder which has 
been proposed by several authors (Browne et al., 1999; Tabrizi et al., 2000; Stoy et 
al., 2005c; Perez-de la Cruz et al., 2009). Altered levels of kynurenic acid and 3HK 
can also be demonstrated in early stage patients or mouse mutants over-expressing 
the huntingtin protein (Guidetti et al., 2000). 
In addition, recent microarray work (Giorgini et al., 2005) on a yeast model 
engineered to over-express huntingtin protein revealed that the most marked 
molecular change induced was an increase in the expression of kynurenine-3-
monoxygenase (KMO), the enzyme promoting the conversion of kynurenine into 3HK 
and, thus, to 3HAA and quinolinic acid.  
Although the use of peripheral measurements of compounds to reflect activity 
within the CNS is fraught with difficulties, since distinguishing central from peripheral 
sources is difficult to achieve, it has been possible to show changes in tryptophan 
metabolites that support direct measurements of their levels in post-mortem brain or 
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animal models (Stoy et al., 2005c). In addition, parallel studies of cytokine levels in 
blood and CSF have shown strictly comparable changes, leading to the suggestion 
that the genetic alteration in huntingtin expression - known to occur in peripheral 
tissues as well as the CNS – is associated with activation of both peripheral 
monocytes/macrophages and central microglia (Sapp et al., 2001; Bjorkqvist et al., 
2008). One consequence of this is that blood measurements are likely to reflect the 
same qualitative changes occurring in the CNS, even if the compounds measured 
are of peripheral origin. However, this assertion needs to be qualified by emphasising 
that only some components of the kynurenine pathway – such as tryptophan itself 
and kynurenine - cross the blood-brain barrier readily using the large neutral amino 
acid transporter (Fukui et al., 1991; Vecsei et al., 1992, Jauch et al., 1993), whereas 
kynurenic acid and 3HAA cross poorly by diffusion alone. 
An increased k:t ratio suggests a degree of immune activation in the HD 
patients. This is consistent with a previous report by Leblhuber et al., (1998) in which 
patients with HD were shown to have increased levels of inflammatory markers such 
as neopterin, immunoglobulin IgA, soluble receptor for tumour necrosis factor-α 
(sTNF-R) and the IL-2 receptor sIL-2R. These changes were associated with a 
significant reduction in blood tryptophan levels consistent with an activation of IDO, a 
finding confirmed in the present study. In addition, the presence of an altered 
inflammatory state in HD is supported by recent data from Bjorkqvist et al., (2008) 
showing raised levels of several cytokines in both plasma and CSF. Their data are 
consistent with the view that innate immune cells are autonomously activated either 
by intrinsic huntingtin-related abnormalities and/or by alterations in immune 
responsiveness to toll-like receptors (TLRs) or other receptor inputs, resulting in a 
disturbed balance of pro- and anti-inflammatory cytokines in the blood and CSF 
characteristic of chronic inflammatory conditions (Stoy 2005a,b; Bunt et al., 2009). 
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The most sensitive blood marker of presymptomatic HD was IL-6 (Bjorkqvist et al. 
2008), elevated up to a mean of 16 years before first clinical disease manifestations. 
Against this background we chose to measure the levels of IL-23, which is an innate 
pro-inflammatory member of the IL-12 family, that induces IL-17 from a subset of T 
cells (Th-17). We found that that there was a significant correlation between levels of 
IL-23 and both the concentration of kynurenic acid and the k:t ratio (signifying 
kynurenine pathway activation) as well as anthranilic acid, which we have previously 
noted to be increased in the presence of inflammation (Forrest et al., 2006) or brain 
damage (Mackay et al., 2006; Darlington et al., 2007).  
Although IL-6 is considered important for commitment to the Th17 lineage, IL-
17 output of memory T cells is primarily sustained by IL-23. Both CD4+ and CD8+ T 
cells can express IL-23 receptors.  Given the known immuno-suppressive properties 
of IDO, it is noteworthy that in murine collagen-induced arthritis, IDO upregulation 
occurs in lymph node dendritic cells and is associated with decreased production of 
IL-17 and IFN-γ from Th-17 and Th1 cells that subsequently become located in 
inflamed joints (Criado 2009). A recent study has demonstrated probable constitutive 
expression of functional IL-17 receptors on murine microglia, and to a lesser extent 
astrocytes, and these respond actively to IL-17, as evidenced by the induction of 
chemokines such as monocyte chemoattractant protein-1 (MCP-1) and macrophage 
inflammatory protein-2. With respect to HD, there is accumulating evidence that 
huntingtin-derived N-terminal oligomers trigger microglial activation through receptors 
of the innate immune system (Haass and Selkoe, 2007; Thakur et al., 2009). It is 
interesting to speculate that the activation profile of such microglia might include 
upregulation of IL-23 alongside IL-6 and IL-8. 
The view that immune activation is involved in HD pathogenesis is further 
expanded by our data on sHLA-G. A wide range of values for sHLA-G were found in 
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the subjects tested here, ranging from undetectable to very high levels of around 
100U/ml. A similar degree of variation has been described by other groups (Hunt et 
al., 2000). Despite this variation, there was a trend for the levels to increase with 
disease severity and huntingtin gene expansion (Fig. 5C), with the changes being 
statistically significant in the most severely affected group of patients.  
sHLA-G has potent immunosuppressive properties. It is present in brain and 
CSF in multiple sclerosis, in which it correlates positively with remission and IFN-β 
therapy (Wiendl et al., 2005; Fainardi et al., 2006), and has recently been  found in 
blood and CSF in several other inflammatory conditions of the CNS (Feger et al. 
2007; Wiendl, 2007). It induces apoptosis of activated CD8(+) T cells and inhibits 
proliferation of CD4(+) T cells and may play a role in the suppression of tumour 
growth and T cell activity associated with a maternal immune system attack on 
developing allogeneic embryos (Moreau et al., 1998; Fuzzi et al., 2002; Carosella et 
al., 2003a,b). It is known that a similar function attaches to the activation of IDO. 
Enzyme activity in the pregnant mother prevents abortion of allogeneic fetuses, while 
inhibition of IDO leads to the loss of embryos (Munn et al., 1998). It could be, 
therefore, that there is a close mechanistic relationship between the activation of IDO 
and the expression of sHLA-G. A recent review (Pistoia et al., 2007) noted the 
uncertainty about whether sHLA-G levels were related to other immune system 
markers and about the factors which regulated the levels of sHLA-G in tissue fluids. 
This suggestion is entirely consistent with evidence that the activation of IDO may 
play a role in the expression of sHLA-G. Both kynurenine (Lopez et al., 2006) and 
3HAA (Lopez et al., 2008) can increase the expression of sHLA-G in macrophages, 
(although kynurenine might act indirectly after its conversion to 3HAA). Alternatively, 
since sHLA-G has been shown to induce the expression and release of IFN-γ from 
blood mononuclear cells (Kanai et al., 2001), it may be that sHLA-G indirectly (via 
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IFN-γ) produces the activation of IDO and, thus, kynurenine production.  
Furthermore, under various conditions of immunostimulation or immunosuppression 
(autoimmunity, allergy, cancer) IFN-α, IFN-β, IFN-γ or IL-10 have all been shown to 
increase the release of sHLA-G from peripheral blood monocytes (and by implication 
microglia), suggesting that sHLA-G might be acting rather like an innate immune 
system 'rheostat' (Borghi et al., 2008, Mapp et al., 2009, Rebmann V et al., 2003). 
There is clearly potential here for the emergence of feedback loops with a major 
influence on immunological and neuronal function.  
It has also been noted that IDO activity can modify the expression of sHLA-G 
(Gonzalez-Hernandez et al., 2005), and the existence of a relationship is supported 
by our finding correlations between this antigen and levels of tryptophan (Table 1). 
There is evidence that sHLA-G and IDO inhibit T-cell proliferation by independent 
molecular pathways (Le Rond et al., 2005), and that neither the antigen nor 
tryptophan and its metabolites are able to modulate the activities of the other system. 
In addition, the interactions noted by Gonzalez-Hernandez et al., (2005) appeared to 
be related to IDO activity independently of its ability to oxidise tryptophan along the 
kynurenine pathway. 
 Overall, the correlations between HD parameters and the kynurenine 
metabolites are consistent with a role for these compounds in HD. The secretion of 
cytokines induced by damaged neurons expressing mutant huntingtin can produce 
microglial activation, including IDO, with the production of 3HK and quinolinic acid 
which could then contribute to further damage (Schwarcz et al., 2002). In yeast cells 
expressing an abnormal expanded huntingtin protein, inhibiting the kynurenine 
pathway reduced poly-Q-mediated toxicity as well as the generation of 3-HK, 
quinolinic acid and reactive radicals. Furthermore, a high-throughput screen of 
compounds using the yeast model led to the identification of a molecule which 
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prevented neurodegeneration induced by polyQ (Zhang et al., 2005).  The active 
compound proved to be an analogue of the KMO inhibitor Ro61-8048, and the results 
suggest that the inhibition of KMO may counteract huntingtin-mediated toxicity.  
In conclusion, our data suggests that the kynurenine pathway may be 
associated with the pathogenesis of HD.  We have also found correlations involving 
kynurenines, IL-23, sHLA-G and disease severity. Taken together, our data supports 
the emerging view that the balance of neurodegeneration and neuroprotection is not 
determined purely by neuronally autononomous mechanisms but is significantly 
impacted by a network of peripherally and centrally acting cytokines and signalling 
molecules that modulate inflammatory and immune responses. More detailed 
analysis of this network in HD model systems and further investigation of KMO and 
perhaps other enzymes in the kynurenine pathway may well reveal new drug targets 
for the treatment of Huntington’s disease. 
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Figure 1 
A schematic summary of the main components of the kynurenine pathway for the 
oxidation of tryptophan.  
 
 
Figure 2 
Levels of tryptophan, kynurenine and the kynurenine:tryptophan ratio (k:t ratio) in 
control  subjects or patients at different stages of Huntington's disease. The columns 
indicate the mean ± s.e.mean for subjects with no gene expansion and no overt 
clinical symptoms (group 0-, controls and relatives of HD patients), those with CAG 
expansion but no symptoms (0+), as well as patients with CAG expansions and mild-
to-moderate disease symptoms (1+) or severe symptoms (2+).  
*p<0.05, **p<0.01 relative to the control group. 
 
 
Figure 3 
Levels of kynurenic acid, 3-hydroxyanthranilic acid (3HAA) and anthranilic acid (AA) 
in control subjects or patients at different stages of Huntington's disease. The 
columns indicate the mean ± s.e.mean for subjects with no gene expansion and no 
overt clinical symptoms (group 0-, controls and relatives of HD patients), those with 
CAG expansion but no symptoms (0+), as well as patients with CAG expansions and 
mild-to-moderate disease symptoms (1+) or severe symptoms (2+).  
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Figure 4 
Bar chart of the age distribution of the subjects examined in this study. There were 
no significant differences in the age of subjects in the various categories compared 
with the control group. 
 
 
Figure 5 
Levels of lipid peroxidation products, IL-23 and sHLA-G in control  subjects or 
patients at different stages of Huntington's disease. The columns indicate the mean ± 
s.e.mean for subjects with no gene expansion and no overt clinical symptoms (group 
0-, controls and relatives of HD patients), those with CAG expansion but no 
symptoms (0+), as well as patients with CAG expansions and mild-to-moderate 
disease symptoms (1+) or severe symptoms (2+).  
*p<0.05, **p<0.01 relative to the control group. 
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 Table 1  
Significant correlations between levels of tryptophan metabolites and clinical 
parameters, showing Spearman correlation coefficient and p value where significant.  
 
 Symptom 
group 
Age CAG 
length 
IL-23 SHLA-G 
Tryptophan  - 0.427 
p=0.000002 
 -  - 0.325 
p=0.00043 
 -  0.224 
p=0.017 
Kynurenine   -  0.405 
p=0.000009
 -   -   -  
K:T ratio 0.354 
p=0.0001 
0.434 
p=0.000001
0.281 
p=0.0025 
 0.190 
p=0.046  
 -  
Kynurenic 
acid  
 -   -   -  0.191 
p=0.045 
- 
3HAA 
 
 -   -   -  -   -  
AA  -  0.275 
p=0.0032 
 -  0.192 
p=0.043 
 -  
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